Neuroendocrine markers insulinoma-associated protein 1, chromogranin, synaptophysin, and CD56 show rare positivity in adenocarcinoma ex-goblet cell carcinoids by Yang, Chen et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
6-1-2019 
Neuroendocrine markers insulinoma-associated protein 1, 
chromogranin, synaptophysin, and CD56 show rare positivity in 





Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Articles © The authors   |   Journal compilation ©  Gastroenterol Res and Elmer Press Inc™   |   www.gastrores.org
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits 
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited
120
Original Article  Gastroenterol Res. 2019;12(3):120-127
Neuroendocrine Markers Insulinoma-Associated Protein 
1, Chromogranin, Synaptophysin, and CD56 Show Rare 
Positivity in Adenocarcinoma Ex-Goblet Cell Carcinoids
Chen Yanga, Ivan Gonzalezb, Lingxin Zhangc, Dengfeng Caob, d
Abstract
Background: Adenocarcinoma ex-goblet cell carcinoid (AdexGCC) 
was considered a neuroendocrine adenocarcinoma, despite major-
ity of tumor cells being negative for conventional neuroendocrine 
markers such as chromogranin and synaptophysin. Recently, insu-
linoma-associated protein 1 (INSM1) has been identified as a novel 
neuroendocrine marker that is more sensitive than chromogranin, 
synaptophysin, and CD56 in pulmonary neuroendocrine tumors.
Methods: We studied this marker in conjunction with chromogranin, 
synaptophysin, and CD56 in 36 appendiceal AdexGCCs (21 prima-
ries, 15 metastatic).
Results: Primary AdexGCCs showed staining for INSM1, chro-
mogranin, synaptophysin, and CD56 in 13/21 (62%), 18/21 (86%), 
18/21 (86%), and 9/19 (47%) cases, respectively. However, the mean 
proportion of tumor cells stained for INSM1, chromogranin, synapto-
physin, and CD56 was only 8.0% (median 1%, range 0-70%), 15.7% 
(median 2%, range 0-70%), 19.9% (median 5%, range 0-90%), and 
5.6% (median 0%, range 0-50%), respectively. Metastatic AdexGCCs 
showed staining for INSM1, chromogranin, synaptophysin, and CD56 
in 8/15 (53%), 11/15 (73%), 12/15 (80%), and 3/14 (21%) cases. The 
mean proportion of tumor cells stained for INSM1, chromogranin, 
synaptophysin, and CD56 in metastatic tumors was 1% (median 1%, 
range 0-3%), 12% (median 1%, range 0-85%), 17% (median 5%, 
range 0-85%), and 2% (median 0%, range 0-20%), respectively.
Conclusions: Primary and metastatic AdexGCCs showed no differ-
ence in INSM1, chromogranin, synaptophysin, or CD56 staining. 
INSM1 exhibits low expression in AdexGCCs and is expressed by a 
lower proportion of tumor cells compared to chromogranin and syn-
aptophysin.
Keywords: Adenocarcinoma ex-goblet cell carcinoid; Neuroendo-
crine; Insulinoma-associated protein 1; Chromogranin; Synaptophysin
Introduction
Appendiceal goblet cell carcinoid (GCC) and adenocarcinoma 
ex-goblet cell carcinoid (AdexGCC) have previously been 
described as two entities in a spectrum of neoplasms show-
ing both glandular/mucinous and neuroendocrine differentia-
tion [1]. Conventional neuroendocrine markers, such as chro-
mogranin and synaptophysin, however, are often negative or 
focally positive in these tumors [2, 3]. Hristov et al previously 
demonstrated that chromogranin and synaptophysin were only 
expressed in 37% and 30% of AdexGCCs, respectively [2]. 
This is in keeping with ultrastructural studies in GCCs that 
showed the presence of abundant mucinous vacuoles, in com-
parison with the extremely difficult to locate, occasional mem-
brane-bound, electron-dense granules [3]. In contrast, conven-
tional carcinoids are often diffusely positive for chromogranin 
and synaptophysin, with abundant electron-dense granules on 
electron microscopy [4].
Molecular and proteomics profiling of neuroendocrine ne-
oplasms have identified several proteins that play a pivotal role 
in neuroendocrine differentiation. Amongst them, one of the 
best characterized is insulinoma-associated protein 1 (INSM1), 
a zinc-finger transcription factor initially isolated from pancre-
atic insulinomas [5]. INSM1 is the upstream transcription fac-
tor for chromogranin [6]. As laboratory evidence began to ac-
cumulate, INSM1 has gained attention in clinical medicine as 
well and has been recently evaluated as a diagnostic marker of 
neuroendocrine differentiation in human tumor tissue samples 
[7, 8]. Rosenbaum et al was the first to demonstrate INSM1 
to be 92.7% sensitive and 95.8% specific in showing neu-
roendocrine or neuroepithelial differentiation [7]. Rooper et 
al further established INSM1 as a pan-neuroendocrine marker 
more sensitive than chromogranin, synaptophysin, and CD56 
combined in pulmonary neuroendocrine neoplasms [8]. How-
ever, no studies have looked at INSM1 expression in GCCs 
or AdexGCCs. Studies to date have mainly focused on pure 
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neuroendocrine neoplasms, neglecting tumors with mixed 
phenotype. The purpose of this study was to investigate this 
novel marker in AdexGCCs, an entity thought to show mixed 
glandular/mucinous and neuroendocrine differentiation.
Materials and Methods
Case selection
The study was approved by the Institutional Review Board of 
Washington University School of Medicine. The surgical pa-
thology archives from 1990 to 2017 of the Washington Uni-
versity Pathology and Immunology Department were searched 
for appendiceal AdexGCCs (primary and metastatic). Ar-
chived hematoxylin and eosin slides and immunohistochem-
istry stains were retrieved and reviewed in consensus by three 
pathologists (CY, LZ, and DC) to confirm the diagnosis. To 
ensure consistency in classification, only cases featuring both 
the diagnostic crypt-like architecture [1] and diffuse strong 
SATB2 positivity, as shown in our previous studies [9, 10] 
were included. In total, 36 appendiceal AdexGCCs (21 prima-
ries, 15 metastases) were enrolled in our study.
Immunohistochemistry
Whole tissue paraffin blocks containing adenocarcinoma com-
ponent for each case was selected. Sections were cut at 5 µm 
thickness, deparaffinized and subjected to antigen retrieval. Im-
munohistochemistry was performed on all cases with mono-
clonal antibodies to INSM1 (Santa Cruz Biotechnology, Clone 
A8, 1:200 dilution), chromogranin (Ventana, clone LK2H10, 
prediluted), synaptophysin (Cell Marque, Clone MRQ-40, pre-
diluted), and CD56 (Ventana, clone MRQ-42, prediluted) on a 
Ventana Benchmark-XT automated stainer using the Ventana ul-
traView DAB detection kit. Positive control (lung carcinoid) and 
negative control (incubation with secondary antibody only) were 
included for each run of immunohistochemistry stains. The tests 
were performed with full ethical compliance as a human study.
Scoring and statistical analysis
Only nuclear staining for INSM1, cytoplasmic staining for 
both chromogranin and synaptophysin, and membranous 
staining for CD56 were considered as positive. The percent-
age of tumor cells stained was visually estimated and semi-
quantitatively scored as 0 (< 1% cells staining), 1+ (1-25%), 
2+ (26-50%), 3+ (51-75%), and 4+ (76-100%). Chi-square test 
was used to compare the staining patterns, and Mann-Whitney 
U test to compare the mean percentage of tumor cells stained. 
A P-value of less than 0.05 was considered statistically sig-
nificant.
Results
Primary adenocarcinoma ex-goblet cell carcinoids
Primary AdexGCCs showed staining for INSM1, chromogra-
nin, synaptophysin, and CD56 in 13/21 (62%, 1+ in 11, 2+ in 
one, 3+ in one), 18/21 (86%, 1+ in 14, 2+ in two, 3+ in two), 
18/21 (86%, 1+ in 13, 3+ in three, 4+ in two), and 9/19 (47%, 
1+ in eight, 2+ in one) cases (Table 1), respectively (INSM1 
vs. chromogranin, P = 0.079; INSM1 vs. synaptophysin, P = 
0.079; INSM1 vs. CD56, P = 0.356; chromogranin vs. syn-
aptophysin, P = 1.000; chromogranin vs. CD56, P = 0.010; 
synaptophysin vs. CD56, P = 0.010). The mean number of tu-
mor cells stained for INSM1, chromogranin, synaptophysin, 
and CD56 was 8.0% (median 1%, range 0-70%), 15.7% (me-
dian 2%, range 0-70%), 19.9% (median 5%, range 0-90%), 
and 5.6% (median 0%, range 0-50%), respectively (INSM1 
vs. chromogranin, P = 0.096; INSM1 vs. synaptophysin, P = 
0.021; INSM1 vs. CD56, P = 0.433; chromogranin vs. synap-
tophysin, P = 0.368; chromogranin vs. CD56, P = 0.030; syn-
aptophysin vs. CD56, P = 0.009). High versus low grade areas 
showed no difference in staining.
Metastatic adenocarcinoma ex-goblet cell carcinoids
Metastatic AdexGCCs showed staining for INSM1, chro-
mogranin, synaptophysin, and CD56 in 8/15 (53%, 1+ in eight), 
11/15 (73%, 1+ in nine, 3+ in one, 4+ in one), 12/15 (80%, 1+ 
in nine, 2+ in one, 3+ in one, 4+ in one), and 3/14 (21%, 1+ in 
three) cases (Table 2), respectively (INSM1 vs. chromogranin, 
P = 0.026; INSM1 vs. synaptophysin, P = 0.121; INSM1 vs. 
CD56, P = 0.077; chromogranin vs. synaptophysin, P = 0.666; 
chromogranin vs. CD56, P = 0.005; synaptophysin vs. CD56, P 
Table 1.  Primary Adenocarcinoma Ex-Goblet Cell Carcinoid 
Results (N = 21)
0 1+ 2+ 3+ 4+
CG 3 14 2 2 0
SYN 3 13 0 3 2
INSM1 8 11 1 1 0
CD56 10 8 1 0 0
CG: chromogranin; SYN: synaptophysin. Scoring criteria: 0 (< 1% cells 
staining), 1+ (1-25%), 2+ (26-50%), 3+ (51-75%), and 4+ (76-100%).
Table 2.  Metastatic Adenocarcinoma Ex-Goblet Cell Carcinoid 
Results (N = 15)
0 1+ 2+ 3+ 4+
CG 4 9 0 1 1
SYN 3 9 1 1 1
INSM1 7 8 0 0 0
CD56 11 3 0 0 0
CG: chromogranin; SYN: synaptophysin. Scoring criteria: 0 (< 1% cells 
staining), 1+ (1-25%), 2+ (26-50%), 3+ (51-75%), and 4+ (76-100%).
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= 0.002). The mean number of tumor cells stained for INSM1, 
chromogranin, synaptophysin, and CD56 in metastatic tumors 
was 1% (median 1%, range 0-3%), 12% (median 1%, range 
0-85%), 17% (median 5%, range 0-85%), and 2% (median 
0%, range 0-20%), respectively (INSM1 vs. chromogranin, 
P = 0.053; INSM1 vs. synaptophysin, P = 0.002; INSM1 vs. 
CD56, P = 0.241; chromogranin vs. synaptophysin, P = 0.166; 
chromogranin vs. CD56, P = 0.011; synaptophysin vs. CD56, 
P = 0.002).
Comparison between primary and metastatic AdexGCCs
Primary and metastatic AdexGCCs showed no difference in 
INSM1, chromogranin, synaptophysin, or CD56 staining 
(INSM1, P = 0.30; chromogranin, P = 0.54; synaptophysin, P 
= 0.98; CD56, P = 0.18). The immunohistochemistry staining 
results for primary and metastatic AdexGCCs are summarized 
in Tables 1 and 2, respectively.
Discussion
The term goblet cell carcinoid was initially coined in by Sub-
buswamy et al in 1974, when they described 12 morphologi-
cally distinct tumors in the vermiform appendix exhibiting 
histologic features different from ordinary carcinoids and colo-
rectal adenocarcinomas [11]. Inclusion of word “carcinoid” in 
the nomenclature was justified by the well-differentiated ap-
pearance on histology and basal glandular position of the tu-
mor. The term “carcinoid” was mainly adopted to emphasize 
the favorable prognosis. It is, however, important to take into 
consideration that most cases in their series were incidental 
findings in patients with appendicitis presenting at low clinical 
stage.
Two subsequent studies evaluated the neuroendocrine fea-
tures of goblet cell carcinoids. Warkel et al [12] demonstrated 
in 1978 the lack of dysplasia in the adjacent appendiceal mu-
cosa in these tumors. They also found concentration of tumor 
elements below the crypts of Lieberkuhn. Argentaffin or ar-
gyrophil granules were seen in 88% of cases. The above find-
ings would argue that goblet cell carcinoids are different from 
conventional adenocarcinomas. In addition, they observed that 
GCCs may not behave as indolent as originally described: 15% 
(6/39) of their patients developed metastatic disease. A year 
later, Warner et al [13] examined GCCs under electron micros-
copy and revealed pleomorphic neurosecretory-type granules 
in these tumors. They observed tumors cells of GCC which 
have abundant mucin to contain granules, only to a lesser ex-
tent than true neuroendocrine tumor cells. The accumulating 
evidence would establish goblet cell carcinoids to be partially 
neuroendocrine in nature.
Despite ultrastructural studies showing evidence of neu-
rosecretory-type granules in GCCs, electron-dense granules 
are sparse compared to conventional carcinoids. Immunohis-
tochemistry studies have also continuously failed to confirm 
extensive neuroendocrine differentiation. Conventional neu-
roendocrine markers, such as chromogranin and synaptophy-
sin, have been shown to be negative or only focally positive in 
GCCs and AdexGCCs. Our study differs from prior approach-
es in three key aspects. First, we focused on AdexGCCs, which 
might be of more clinical relevance since systemic therapy is 
more often considered. Second, our study utilizes INSM1, a 
nuclear stain that harbor minimal background staining, which 
is advantageous compared to the cytoplasmic or membranous 
staining of conventional neuroendocrine markers, especially 
in mucin-rich tumors. Finally, our cases have confirmed di-
agnosis by both histology and immunohistochemistry [9, 10]. 
In summary, our study sets to investigate the phenotype of 
AdexGCC using classic neuroendocrine markers chromogra-
nin, synaptophysin, and CD56, in addition to new neuroendo-
crine marker INSM1.
Our results show INSM1 to be positive in 58% (21/36) of 
AdexGCC cases (62% of primary cases and 53% of metastatic 
cases). Furthermore, INSM1 shows positivity in only 5% of 
tumor cells (8% in primary cases and 1% in metastatic cases). 
Both chromogranin and synaptophysin prove to be more sensi-
tive when compared with INSM1. Chromogranin is positive 
in 81% (29/36) of AdexGCC cases (86% of primary cases and 
73% of metastatic cases). It is positive in 14% of tumor cells 
(16% in primary cases and 12% in metastatic cases). Similarly, 
synaptophysin is positive in 83% (30/36) of AdexGCC cases 
(86% of primary cases and 80% of metastatic cases). A higher 
percentage of 19% of tumor cells (20% in primary cases and 
17% in metastatic cases) stains positive for this marker. In con-
trast, CD56 is the least sensitive of the four markers, being pos-
itive in only 36% (12/33) of AdexGCC cases (47% of primary 
cases and 21% of metastatic cases). Rare staining is also more 
commonly seen with CD56, with only 4% of cells positive (6% 
in primary cases and 2% in metastatic cases). The percentage 
of cells positive is shown in Figure 1, which shows the major-
Figure 1. All studied neuroendocrine markers exhibit negative to fo-
cal expression pattern in adenocarcinoma ex-goblet cell carcinoids 
(primary and metastatic). The majority of cases show less than 10% 
staining of tumor cells with any neuroendocrine marker. Synaptophysin 
stain shows highest percentage of positivity, followed by chromogranin, 
then INSM1, with CD56 showing least percentage of positive cells. CG: 
chromogranin; SYN: synaptophysin.
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ity of cases with less than 5% of cells positive for these neu-
roendocrine markers. Neuroendocrine phenotype, if present, is 
definitely not predominant, and would explain why neuroendo-
crine therapy regimens are not recommended for the treatment 
of AdexGCCs. As shown in our study, only five of the primary 
AdexGCCs show diffuse (> 50%) staining for any neuroendo-
crine marker, and only two of the metastatic AdexGCCs show 
diffuse (> 50%) staining for any neuroendocrine marker (Fig. 
2). Most cases show either very focal positivity (Fig. 3) or are 
completely devoid of any neuroendocrine marker expression 
(Fig. 4). While there are still cases that show greater than 50% 
tumor cells staining for either chromogranin or synaptophysin, 
both these markers are less specific in tumors with abundant 
mucin given their non-nuclear staining pattern. We have also 
observed chromogranin and synaptophysin to be positive in 
approximately 11% and 30% of tumor cells in gastric signet 
ring cell carcinomas, respectively (unpublished data).
Recent molecular studies have shown these tumors to be 
different genetically from conventional carcinoids and colo-
rectal adenocarcinomas. Mutational landscape studies on 
AdexGCCs showed tumor cell mutation which were not com-
monly seen in colorectal adenocarcinomas such as USP9X, 
NOTCH1, CTNNA1, CTNNB1, TRRAP, ARID1A, ARID2, 
CDH1, RHPN2, MLL2, RHOA, SOX9, and KDM6A [14-16]. 
The mutations usually associated with colorectal adenocarci-
nomas, such as TP53, KRAS, and APC, were only identified 
in rare cases of AdexGCCs [16]. Neuroendocrine tumors did 
not show driver mutations in one study, but this could be due 
to the small number of cases enrolled [14]. Johncilla et al [15] 
demonstrated that there is overlap in mutational landscape in 
GCC and AdexGCC, further evidence supporting that GCC 
and AdexGCC are within spectrums of the same entity, rather 
than two distinct histological types. Overall, the mutational 
landscape of GCCs and AdexGCCs are different from both 
conventional neuroendocrine tumors and colorectal adenocar-
cinomas, suggesting that they are a separate entity.
Prognostic studies also show that these tumors are distinct 
from neuroendocrine tumors and actually share more simi-
Figure 2. A case of adenocarcinoma ex-goblet cell carcinoid with positive staining for INSM1, chromogranin, and synaptophysin 
in the goblet cell component. There is diffuse staining of all three markers in the tumor cells. (A) Hematoxylin and eosin. (B) 
INSM1. (C) Chromogranin. (D) Synaptophysin.
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larities with colorectal adenocarcinomas. Most recently, Yozu 
et al [17] showed using their model of grading and staging 
AdexGCCs like other tubal gut adenocarcinomas, they can 
better separate patients into prognostic groups. Current surgi-
cal and oncologic approaches would favor them to be classi-
fied like an adenocarcinoma since mainstream treatment in-
cludes right hemicolectomy. The American Joint Committee 
on Cancer/Tumor-Node-Metastasis classification staging for 
AdexGCC of the appendix is similar to staging of primary ad-
enocarcinoma of the appendix [18].
It had been shown in biological studies that cells in GCCs 
and AdexGCCs produce lysozyme and have a secretory com-
ponent, which is more similar to intestinal crypts and not con-
sistent with neuroendocrine cells [19]. This is in keeping with 
recent findings that supports the fact that GCCs and AdexGC-
Cs have been hypothesized to origin from the crypt cells in the 
intestine, through differentiation through the MATH1 pathway 
rather than the NOTCH pathway [20, 21], which can be seen in 
the secretory crypt cells. The same cells that are thought to dif-
ferentiate through this pathway are neuroendocrine and Paneth 
cells. This might be one of the reasons that neuroendocrine 
markers such as synaptophysin and chromogranin are not pro-
portionally, and only focally, expressed in these tumors. The 
hypothesis is that Paneth cells are thought to be differentiated 
through GFI1/SOX9 pathway, while goblet cells are differenti-
ated through GFI1/KLF4 pathway, and finally neuroendocrine 
cells are differentiated with neurogenin 3 pathway. All three 
pathways are downstream of the MATH1 pathway. It is likely 
because of the close proximity in terms of the location in the 
tubal gut mucosa of these three cell types, and the fact that they 
share a common MATH1 pathway, that these three cell types 
can be seen intermixed in GCCs and occasionally AdexGCCs. 
Our study highlights the fact that AdexGCCs show either neg-
ative or limited expression of the four neuroendocrine markers 
studied, and in conjunction of additional evidence in molecu-
lar and prognostic studies, support separating AdexGCC from 
carcinoids or neuroendocrine tumor.
While our analysis is the first to comprehensively evalu-
Figure 3. A case of adenocarcinoma ex-goblet cell carcinoid with weak positive staining for chromogranin and synaptophysin, 
but negative for INSM1. Note that chromogranin and synaptophysin are only expressed in a small proportion of tumor cells. (A) 
Hematoxylin and eosin. (B) INSM1. (C) Chromogranin. (D) Synaptophysin.
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ate novel neuroendocrine marker INSM1 in AdexGCCs along 
with three conventional neuroendocrine markers chromogra-
nin, synaptophysin, and CD56, there are several limitations 
that merit discussion. First, our study was a retrospective im-
munohistochemistry study, and was limited by the inherent 
bias in studies of this type. Second, the number of cases in-
cluded in our study is fairly small, due to the relatively low 
prevalence of these tumors. Thirdly, all the cases came from 
the same institution, thus a patient population selection bias 
could not have been avoided. Finally, follow-up information 
was not available for most of the cases, so the relevance of 
neuroendocrine marker expression and prognosis cannot be 
elucidated. Further prospective multi-institutional studies with 
more clinical intervention data would be needed to address the 
above issues.
Conclusions
We investigate novel neuroendocrine marker INSM1 in 
AdexGCCs and found that it is often negative or shows only 
focal positivity in limited tumor cells. Our study highlights 
that INSM1, along with conventional neuroendocrine mark-
ers, such as chromogranin, synaptophysin, and CD56 shows 
a different staining pattern when compared with carcinoids or 
true neuroendocrine carcinomas. Along with emerging clin-
icopathologic and molecular evidence, AdexGCCs should be 
distinguished from a neuroendocrine tumor.
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